| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
52,992 | 51,480 | 43,384 | 72,631 | 58,139 |
|
Cost of Revenue
|
-26,733 | -26,465 | -21,902 | -34,231 | -33,727 |
|
Gross Profit
|
26,259 | 25,015 | 21,482 | 38,400 | 24,412 |
| Selling, General and Administrative Expenses
|
-20,737 | -19,729 | -18,131 | -23,252 | -23,519 |
|
Research and Development Expenses
|
-5,947 | -6,701 | -6,977 | -9,442 | -8,570 |
|
Operating Income/Expenses
|
-26,684 | -26,430 | -25,108 | -32,694 | -32,089 |
|
Total Operating Profit/Loss
|
-425 | -1,415 | -3,626 | 5,706 | -7,677 |
| Total Net Finance Income/Expense
|
261 | 198 | 147 | -255 | -208 |
| Irregular Income/Expenses
|
-- | -- | -- | -- | 0 |
|
Other Income/Expense, Non-Operating
|
-118 | 133 | -89 | 452 | -16 |
|
Non-Operating Income/Expenses, Total
|
143 | 331 | 58 | 197 | -224 |
|
Pretax Income
|
-282 | -1,084 | -3,568 | 5,903 | -7,901 |
|
Provision for Income Tax
|
-118 | -156 | -6,295 | -1,155 | 1,965 |
|
Net Income from Continuing Operations
|
-400 | -1,240 | -9,863 | 4,748 | -5,936 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-400 | -1,240 | -9,863 | 4,748 | -5,936 |
|
Net Income after Non-Controlling/Minority Interests
|
-400 | -1,240 | -9,863 | 4,748 | -5,936 |
|
Net Income Available to Common Stockholders
|
-400 | -1,240 | -9,863 | 4,748 | -5,936 |
|
Diluted Net Income Available to Common Stockholders
|
-400 | -1,240 | -9,863 | 4,748 | -5,936 |
| Basic EPS
|
-0.04 | -0.12 | -0.99 | 0.48 | -0.60 |
| Diluted EPS
|
-0.04 | -0.12 | -0.99 | 0.47 | -0.60 |
|
Basic Weighted Average Shares Outstanding
|
10,172 | 10,087 | 9,997 | 9,951 | 9,905 |
|
Diluted Weighted Average Shares Outstanding
|
10,210.50 | 10,087 | 9,997 | 10,021 | 9,905 |
|
Reported Normalized Basic EPS
|
-0.26 | -- | -0.26 | 0.60 | -0.60 |
|
Reported Normalized Diluted EPS
|
-0.26 | -- | -0.26 | 0.59 | -0.60 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-543 | -1,282 | -3,715 | 6,158 | -7,693 |
|
EBITDA
|
81 | -610 | -2,678 | 7,647 | -6,361 |
|
Normalized EBITDA
|
2,076 | 1,192 | -1,521 | 9,968 | -5,206 |
|
Normalized Income
|
1,175.26 | 8.20 | -2,550 | 5,906 | -5,936 |
|
Total Unusual Items
|
1,994 | 1,580 | 1,246 | 830 | 1,163 |
12/31/2022 - 8/22/1996
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade